World Lung 2023 – Flaura2 leaves a gap open for J&J
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.